Liquid Biopsy Market Size, Segmentation, Opportunities, Trends, Growth and Industry Forecast To 2022 by Credence Research
According to the latest report published by Credence
Research, Inc. “Liquid
Biopsy Market Growth, Future Prospects and Competitive
Analysis, 2016-2022,” the liquid biopsy market was valued at USD
1,881.9 Mn in 2015, and is expected to reach USD 10,850.3 Mn by 2022, expanding
at a CAGR of 24.7% from 2016 to 2022.
Browse the full report Liquid
Biopsy: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 at http://www.credenceresearch.com/report/liquid-biopsy-market
Market Insights
In the past, tissue samples extracted
through biopsy were evaluated to detected malignancy. However, some micrographs
delivered inconsistent and ambiguous results, thus demanding repeated
procedure. The advent of molecular diagnostics and next generation sequencing
offered pathologists with a powerful tool for efficient diagnosis. Even with
such advances, cancer diagnosis still remained subject to the limitation of
availability of biopsied tissue, which further posed a challenge in case of
monitoring therapy success monitoring. The eventual advent of liquid biopsy
however, overcame this constraint by efficiently employing precise circulating tumor
cells (CTCs) detection and isolation.
In the recent period, the range of
liquid biopsy tools has expanded to incorporation of circulating tumor DNA
(ctDNA) and extracellular vesicles (EVs). ctDNA contains a small fraction of
the patient's cell free DNA; it can be readily evaluated for genetic
inconsistency using target amplification and sequencing tools. In addition, EVs
is currently the latest addition to liquid biopsy portfolio. EVs provide easy
access to biomolecule subsets present in whole cells. EVs based technology is
focused on identifying mutations in mRNA.
Extensive research is being taken
place in the recent years on creating sophisticated analytical tools for
analysis of cancer cells for detecting genetic variation at low allele
frequency. CTCs are first of such units of liquid biopsy. However, advent of
easy isolation of cell-free DNA has provided vital insights that move a step
ahead to that of CTCs. The latest tools of EVs analysis are rapidly gaining
importance on the basis of their potential ability of identifying genetic
variation. The latest CTC technologies employ EpCAM protein for immunocapture,
however this tool demonstrate reduced expression during epithelial to
mesenchymal transition. Other isolation techniques are heavily dependent on
cell size, cellular behavior in electric fields, morphology and deformability.
Scarcity of CTCs in blood has urged researchers to develop evolved methods for
obtaining molecular information from single cells, thus increasing their
potential use in therapy monitoring.
As the commercial interest in this
field is on the rise, several large diagnostics and medical technologies
companies have ventured in this market. Moreover, there is also a significant
rise in the number of startups specializing in the field. Industry giants are
striking deals with pharma and biotech companies to expand application areas of
liquid biopsy.
·
· Request
Free Sample - http://www.credenceresearch.com/sample-request/57830
About
Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we
are
Credence
Research is a worldwide firm, containing more than 15 research consultants and
almost 100 research and information professionals.
Our
customers mirror our worldwide nature. Around 45% are in Europe, 30% in the
Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm
is intended to work as one. We are a solitary global research organization
united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve
customers at each level of their organization, in whatever limit we can be most
helpful, whether as a trusted counsel to top management or as a hands-on mentor
for forefront representatives. For each engagement, we collect a group with the
most suitable experience and ability.
No matter
the challenge, we concentrate on delivering functional and persevering results,
and preparing our customers to develop and lead. We join forces with customers
to place suggestions into practice. Our research specialist work
straightforwardly with customers over long stretches to create workforce
aptitudes, drive operational change, and apply new working strategies.
Contact:
Name: Chris
Smith
Designation: Global
Sales Manager
Ph: +1-800-361-8290
Post a Comment